Literature DB >> 21057159

Prevalence of non alcoholic fatty liver disease in premenopausal, posmenopausal and polycystic ovary syndrome women. The role of estrogens.

Ylse Gutierrez-Grobe1, Guadalupe Ponciano-Rodríguez, Martha H Ramos, Misael Uribe, Nahum Méndez-Sánchez.   

Abstract

BACKGROUND & AIM: Non alcoholic fatty liver disease (NAFLD) is the most common liver disease in Western countries. Population studies have demonstrated that men and posmenopausal women have higher prevalence of NAFLD. The aim was to investigate the prevalence of NAFLD in premenopausal, posmenopausal and polycystic ovary syndrome (PCOS) women.
METHODS: A cross sectional study carried out at University Hospital in Mexico City from January 2009 to November 2009. One hundred ninety seven women who agreed to participate were divided into groups, comprising 93 with NAFLD and without NAFLD. Anthropometric, metabolic and biochemical variables were measured. Serum estradiol and cortisol concentrations were determined and compared between the groups.
RESULTS: Of the 197 patients, 93(47.2%) had NAFLD and 104 (52.8%) did not have NAFLD. The prevalence of NAFLD in premenopausal, postmenopausal and PCOS patients was 32.2, 57.9, and 62%, respectively. Age, BMI, hip to waist ratio, fasting glucose, HOMA -IR, and insulin were significantly higher in NAFLD patients. Women without NAFLD had significantly higher levels of serum estradiol (100 ± 95.4) compared with NAFLD patients (55.5 ± 66.6) p = 0.001. By group with and without NAFLD: premenopausal (55.44±93.3 vs. 128.56 ± 109.22), posmenopausal (44.98 ± 51.41 vs. 42.72 ± 51.48) and PCOS women (64.9 ± 53.3 vs. 101.36 ± 80.89) had significantly different hormone profile.
CONCLUSION: These results suggest that NAFLD is more prevalent in postmenopausal and women with PCOS than those premenopausal ones. The estrogens may have a protective effect of against NAFLD in women.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21057159

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  69 in total

Review 1.  Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: systematic review and meta-analysis.

Authors:  A L L Rocha; L C Faria; T C M Guimarães; G V Moreira; A L Cândido; C A Couto; F M Reis
Journal:  J Endocrinol Invest       Date:  2017-06-13       Impact factor: 4.256

2.  Liver disease in women: the influence of gender on epidemiology, natural history, and patient outcomes.

Authors:  Jennifer Guy; Marion G Peters
Journal:  Gastroenterol Hepatol (N Y)       Date:  2013-10

3.  Cardiovascular Fat, Menopause, and Sex Hormones in Women: The SWAN Cardiovascular Fat Ancillary Study.

Authors:  Samar R El Khoudary; Kelly J Shields; Imke Janssen; Carrie Hanley; Matthew J Budoff; Emma Barinas-Mitchell; Susan A Everson-Rose; Lynda H Powell; Karen A Matthews
Journal:  J Clin Endocrinol Metab       Date:  2015-07-15       Impact factor: 5.958

Review 4.  Polycystic ovary syndrome throughout a woman's life.

Authors:  José Bellver; Luis Rodríguez-Tabernero; Ana Robles; Elkin Muñoz; Francisca Martínez; José Landeras; Juan García-Velasco; Juan Fontes; Mónica Álvarez; Claudio Álvarez; Belén Acevedo
Journal:  J Assist Reprod Genet       Date:  2017-09-27       Impact factor: 3.412

Review 5.  Nonalcoholic fatty liver disease in women with polycystic ovary syndrome.

Authors:  Stavroula A Paschou; Stergios A Polyzos; Panagiotis Anagnostis; Dimitrios G Goulis; Christina Kanaka-Gantenbein; Irene Lambrinoudaki; Neoklis A Georgopoulos; Andromachi Vryonidou
Journal:  Endocrine       Date:  2019-09-19       Impact factor: 3.633

Review 6.  Cardiometabolic Risk in PCOS: More than a Reproductive Disorder.

Authors:  Laura C Torchen
Journal:  Curr Diab Rep       Date:  2017-11-11       Impact factor: 4.810

Review 7.  Endocrine causes of nonalcoholic fatty liver disease.

Authors:  Laura Marino; François R Jornayvaz
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

8.  Fatty liver index vs waist circumference for predicting non-alcoholic fatty liver disease.

Authors:  Nima Motamed; Masoudreza Sohrabi; Hossein Ajdarkosh; Gholamreza Hemmasi; Mansooreh Maadi; Fatemeh Sima Sayeedian; Reza Pirzad; Khadijeh Abedi; Sivil Aghapour; Mojtaba Fallahnezhad; Farhad Zamani
Journal:  World J Gastroenterol       Date:  2016-03-14       Impact factor: 5.742

9.  Prevalence and Severity of Nonalcoholic Fatty Liver Disease in Non-Obese Patients: A Population Study Using Proton-Magnetic Resonance Spectroscopy.

Authors:  Jeremy Lok Wei; Jonathan Chung-Fai Leung; Thomson Chi-Wang Loong; Grace Lai-Hung Wong; David Ka-Wai Yeung; Ruth Suk-Mei Chan; Henry Lik-Yuen Chan; Angel Mei-Ling Chim; Jean Woo; Winnie Chiu-Wing Chu; Vincent Wai-Sun Wong
Journal:  Am J Gastroenterol       Date:  2015-07-28       Impact factor: 10.864

10.  Downregulation of sulfotransferase expression and activity in diseased human livers.

Authors:  Emine B Yalcin; Vijay More; Karissa L Neira; Zhenqiang James Lu; Nathan J Cherrington; Angela L Slitt; Roberta S King
Journal:  Drug Metab Dispos       Date:  2013-06-17       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.